Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. (NYSE: NUVB) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology business, financial position and key agreements. On this page, you can review NUVB’s current reports on Form 8‑K and other SEC filings alongside AI-generated summaries that help explain the significance of each document.
For Nuvation Bio, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources for information on its pipeline of targeted cancer therapies, including taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer, safusidenib for IDH1-mutant gliomas, NUV-868 and its drug-drug conjugate platform. These filings typically describe clinical programs such as the TRUST registrational studies for taletrectinib and the G203 study for safusidenib, as well as risk factors relevant to oncology drug development and commercialization.
Nuvation Bio also uses Form 8‑K to disclose material events. Recent 8‑K filings have reported preliminary financial results and net product revenue for IBTROZI, the entry into a license and collaboration agreement with Eisai Co., Ltd. for taletrectinib in multiple territories, publication of positive Phase 2 data for safusidenib, and strategic decisions such as discontinuation of NUV-1511 while continuing the underlying DDC platform. Other 8‑Ks have furnished earnings press releases and updated corporate presentations.
Investors interested in equity structure and trading can consult registration statements and periodic reports for details on Nuvation Bio’s Class A common stock and redeemable warrants, which trade on the New York Stock Exchange under the symbols NUVB and NUVB.WS. Form 4 insider transaction reports, when available, can be used to track purchases and sales of NUVB securities by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key terms in complex agreements, explain financial disclosures in plain language and point out important milestones, such as collaboration payments or changes in clinical program status. Real-time updates from EDGAR ensure that new NUVB filings appear promptly, while structured views of 10‑K, 10‑Q, 8‑K and Form 4 documents help users quickly locate the information most relevant to their analysis of Nuvation Bio’s oncology business.
David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.
Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.
Key transaction details:
- Transaction type: Direct purchase of common stock
- Total transaction value: ~$893,500
- Filing was signed by Stephen Dang as attorney-in-fact
- No derivative securities were involved in this transaction